The latest biotech news

News and Trends 26 Aug 2022

Aktis Oncology raises millions in funding bringing total to $161M

Aktis Oncology announced yesterday (August 25) that it has raised a series A extension financing of $84 million bringing its total capital raised to date to $161 million. The Massachusetts-based company develops targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. Aktis Oncology‘s investors The extension included participation from new health investors Cowen […]

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […]

August 26, 2022

News and Trends 26 Aug 2022

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […]

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

First gene therapy for adults with severe hemophilia approved by EC

The European Commission (EC) has granted conditional marketing authorization for a gene therapy to treat severe hemophilia A in adults it was announced yesterday (August 25). BioMarin Pharmaceutical Inc.’s Roctavian (valoctocogene roxaparvovec) treats the congenital factor 8 deficiency in adults patients without a history of factor VIII inhibitors without detectable antibodies to adeno-associated virus serotype […]

August 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Ordaōs raises $5M to accelerate drug design and discovery

U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […]

August 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Biotech stocks enjoy brief rally with uncertain winds ahead

Global biotech stocks have briefly risen after sinking steadily over the last year. Whether this recovery lasts is another question. Here are the latest biotech stock trends for 2022. In early 2021, biotech stock markets began a long period where stocks dropped in value caused by investors fleeing the sector. This season, known as a […]

August 25, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 25 Aug 2022

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […]

August 25, 2022 - 3 minutesmins - By Liza Laws

coronavirus COVID 19 Europe biotech lungs

News and Trends 25 Aug 2022

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit in a clinical trial studying the drug, Zorifertinib. Drugs developer, Alpha Biopharma, announced the completion today (August 25) of last patient last visit (LPLV) in its international, multicenter EVEREST phase 2/3 study of the next-generation […]

August 25, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

3T Biosciences launches with $40M financing

3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Scottish researchers can tap into new £300K fund

Precision Medicine Scotland Innovation Centre (PMS-IC), the national center for accelerating the advancement and adoption of precision medicine, has launched a new fund to support Scottish researchers. The $300,000 ($355,000) fund, the first offered by PMS-IC, will support research ideas to support accurate diagnosis and/or treatment based on an individual’s unique biology. Funds of up […]

August 25, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

New drug boosts options for rheumatoid arthritis treatment

In its final phase III clinical trial, a new drug for treating rheumatoid arthritis has proved to be at least as effective as the current “gold standard” treatment for this autoimmune disease. This opens up new treatment options for affected patients. The results of the international multicentre study led by MedUni Vienna were recently published […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic arm of Takeda. TVI investment joins Zelluna’s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical […]

August 25, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Aktis Oncology raises millions in funding bringing total to $161M

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

First gene therapy for adults with severe hemophilia approved by EC

Ordaōs raises $5M to accelerate drug design and discovery

Biotech stocks enjoy brief rally with uncertain winds ahead

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

3T Biosciences launches with $40M financing

Scottish researchers can tap into new £300K fund

New drug boosts options for rheumatoid arthritis treatment

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!